Recent data have demonstrated an upregulation of the tumor-immune system in subjects undergoing chemotherapy by activating CD8+ (Th1) TILs [8], positively correlating with improved responses [10] and even with increased survival [11,12] Similarly, higher CD4-TILs (Th2) have been associated with favorable outcomes [13]. This evidence concerns the gene CD4 and neoplasm.